We are seeking to explore the true story of AI: where are we now, what do we need to overcome, and how should we integrate this technology within the genomics sphere?
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
Scientists have published one of the most detailed maps ever made of structural variations in a cancer cell’s genome.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Personalised medicine has been a goal of researchers and doctors for a long time. Now, researchers have developed what they call a personalised Therapeutic Intervention Fingerprint (pTIF), for patients with neurological disease.
Researchers at Harvard Medical School have found further evidence that supports the notion that viruses could help cause the onset of Alzheimer’s disease; an idea that was once ridiculed by other sceptics and researchers.
Even in light of the rising fears of “superbugs” in the world of big pharma, the marginal profits made through the development of antibiotics isn’t enough to justify the research.
Scientists have developed a technique that shows individual cancer cells in a tumour in real-time, revealing which cells that interact with a drug and which cells the drug fails to reach.
One year after researchers published their work on a physiological test for autism, a follow-up study has confirmed its exceptional success in assessing whether a child is on the autism spectrum.
Scientists have gained a glimpse of how marks on our genes that could be linked to adverse health outcomes in later life behave in the first few days after conception.
Researchers have created an artificial intelligence system for predicting, not simply tracking, potential side effects from drug combinations.
A new analysis shows that the US health care system will save money in the long run by screening people born in Asia and Africa for the hepatitis B virus, which causes liver cancer and cirrhosis.
Researchers have for the first time, used gene-editing tools in adult monkeys to disable a gene throughout much of the liver.